Across the RE‑COVER trials, 9 patients (0.4%) in the dabigatran arms and 5 (0.2%) in the warfarin arms had an acute coronary syndrome event. Of these, 8 patients (0.3%) in the dabigatran arms and 4 (0 ...
Dallas, Nov 18 (Reuters) - An experimental antidote to the widely used blood clot preventer Pradaxa worked immediately and completely in an early-stage trial among healthy volunteers, raising hopes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results